The goal of treatment is a complete cytogenetic response, meaning that there are no cells with the Philadelphia chromosome.
The initial treatment for chronic phase CML is targeted therapy with the drugs imatinib (Gleevec), dasatinib (Sprycel), or nilotinib (Tasigna).
If there is no evidence of the Philadelphia chromosome and the blood cell counts are normal during the initial treatment, patients should continue the medication throughout their lifetime with regular monitoring to see how well the treatment is working.
Bone marrow/stem cell transplantation may be an option if targeted therapy is not effective.
Above information came from here
No comments:
Post a Comment
I love your comments! I will approve and respond as soon as possible. Thank you for posting them.
I'm sorry that Anonymous comments are no longer accepted. I've gotten too many spammers that way. If you would like to comment directly my profile provides a way to do that.